Literature DB >> 12376982

Localised Ewing sarcoma/PNET of bone--prognostic factors and international data comparison.

R Derek Jenkin1, Ibrahim Al-Fawaz, Mohammed Al-Shabanah, Ayman Allam, Mouhab Ayas, Yasser Khafaga, Muhammad Memon, Samira Rifai, Henrik Schultz, Derek Younge.   

Abstract

BACKGROUND: To determine if the distribution of prognostic factors accounted for the differences when the outcome for localised Ewing Sarcoma/PNET bone in Saudi Arabia was compared with results from countries with well developed health care systems. PROCEDURE: Retrospective analysis was undertaken of 163 consecutive patients of all ages, treated with radical intent at KFSHRC from 1975 to 1998. Standard chemotherapy was commenced in all patients. The local treatment modality was resection +/- radiation in 30% and radiation treatment alone in 67%. Size data were available for 51 patients treated from 1994 to 1998, inclusive. One third of these patients had tumors with volume >500 ml.
RESULTS: Three year survival significantly increased with the year of diagnosis, 1975-1988 45%; 1989-1993 55%; and 1993-1998 63% (P = 0.006). Favorable prognostic factors were age < or =14 (P = 0.07); site, distal extremity, and skull (P = 0.08); and volume < or = 200 ml (P = 0.06). Secondary prognostic factors were response to induction chemotherapy, both histological, 100% necrosis, (P = 0.04) and clinical CR+PR, (P = 0.02). From 1994 to 1998, 3 year survival for tumors in the distal extremity and skull was 80% and for small tumors, < 200 ml, at any site was 82%. In comparison, the 3 year survival for patients with tumors at any other sites was 60%, and for tumors >200 ml, 55%.
CONCLUSIONS: Overall survival progressively improved. From 1994 to 1998 the survival of patients with small tumors and/or favorable sites was similar to the best reported results. It was not possible to compare results by tumor size for large tumors, > 500 ml, due to the absence of data from elsewhere. A better staging system is required for the international comparison of results. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12376982     DOI: 10.1002/mpo.10212

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  14 in total

1.  Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group.

Authors:  Aaron Cooper; John van Doorninck; Lingyun Ji; Darren Russell; Marc Ladanyi; Hiroyuki Shimada; Mark Krailo; Richard B Womer; Jessie Hao-ru Hsu; Dafydd Thomas; Timothy J Triche; Richard Sposto; Elizabeth R Lawlor
Journal:  Clin Cancer Res       Date:  2010-11-03       Impact factor: 12.531

Review 2.  Very late local recurrence of Ewing's sarcoma--can you ever say 'cured'? A report of two cases and literature review.

Authors:  S A Hanna; L A David; P D Gikas; A J Tindall; S R Cannon; T W R Briggs
Journal:  Ann R Coll Surg Engl       Date:  2008-10       Impact factor: 1.891

3.  Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  John A van Doorninck; Lingyun Ji; Betty Schaub; Hiroyuki Shimada; Michele R Wing; Mark D Krailo; Stephen L Lessnick; Neyssa Marina; Timothy J Triche; Richard Sposto; Richard B Womer; Elizabeth R Lawlor
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

4.  The novel use of small intestinal submucosal matrix for chest wall reconstruction following Ewing's tumour resection.

Authors:  Feilim Murphy; Martin T Corbally
Journal:  Pediatr Surg Int       Date:  2007-02-08       Impact factor: 1.827

5.  Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population.

Authors:  Kan Yonemori; Umio Yamaguchi; Masayuki Kaneko; Hajime Uno; Masahiro Takeuchi; Masashi Ando; Yasuhiro Fujiwara; Ako Hosono; Atsushi Makimoto; Tadashi Hasegawa; Ryouhei Yokoyama; Fumihiko Nakatani; Akira Kawai; Yasuo Beppu; Hirokazu Chuman
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-09       Impact factor: 4.553

6.  Ewing sarcoma outcomes in a country with limited resources: Egypt as an example.

Authors:  Ahmed Mohammed Morsy; Salah Abdel-Hadi; Khalid Mohammed Rezk; Gamal Amira; Badawy Mohammed Ahmed; Marwa Tammam Hussien; Mahmoud Gamal Ameen; Hosam Eldein Mostafa Kamel; Doaa Mohamed Fouad; Alia Mohamed Attia; Asmaa Salah; Osama Mostafa Abd Elbadee; Ayatallah Ali Yousseif; Marwa Ismail Abdelgawad; Asmaa Hussein Fathy; Yasmine Nagy Elwany; Islam Karam-Allah Ramadan; Khaled Hassan Mosallam; Ahmed Ibrahim Abd Elwahab; Khaled Hashim Mahmoud; Maged Abdel Fattah Amine; Ahmed Refaat Abd Elzaher; Hanan Ahmed Eltyb; Ahmed Mubarak Hefni
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

7.  Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor.

Authors:  Helen J Knowles; Karl-Ludwig Schaefer; Uta Dirksen; Nicholas A Athanasou
Journal:  BMC Cancer       Date:  2010-07-16       Impact factor: 4.430

8.  Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.

Authors:  Alfredo Pinto; Paul Dickman; David Parham
Journal:  Sarcoma       Date:  2010-10-14

9.  Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour.

Authors:  J Vermeulen; S Ballet; O Oberlin; M Peter; G Pierron; E Longavenne; V Laurence; J Kanold; P Chastagner; O Lejars; J-Y Blay; P Marec-Berard; J Michon; O Delattre; G Schleiermacher
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

10.  Ewing sarcoma of the bone in children under 6 years of age.

Authors:  Maria Antonietta De Ioris; Arcangelo Prete; Raffaele Cozza; Marta Podda; Carla Manzitti; Andrea Pession; Elisabetta Schiavello; Benedetta Contoli; Rita Balter; Franca Fagioli; Gianni Bisogno; Loredana Amoroso; Franco Locatelli; Roberto Luksch
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.